How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,142 results for

Mycobacterium Avium Complex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Mycobacterium avium complex pulmonary disease: new epidemiology and management concepts. (PubMed)

Mycobacterium avium complex pulmonary disease: new epidemiology and management concepts. The prevalence of Mycobacterium avium complex (MAC)-related pulmonary disease has been increasing because of environmental factors, changes in organism virulence, and evolving host susceptibility. Treatment is often complicated by adverse effects, development of drug resistance, and refractory disease, with recurrence rates as high as 25-45%.Aerosolization of water, soil, or dusts are the likely sources

2018 Current Opinion in Infectious Diseases

22. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. (PubMed)

Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Patients with refractory Mycobacterium avium complex lung disease (MAC-LD) undergo long-term macrolide therapy, but macrolide resistance develops infrequently.The aim of this study was to determine whether reinfection was a factor in the low incidence of macrolide resistance in patients with refractory MAC-LD.Among 481 patients with treatment-naive MAC-LD who started antibiotic treatment

2018 American Journal of Respiratory and Critical Care Medicine

23. Chylous ascites as a complication of intraabdominal Mycobacterium avium complex immune reconstitution inflammatory syndrome (PubMed)

Chylous ascites as a complication of intraabdominal Mycobacterium avium complex immune reconstitution inflammatory syndrome Chylous ascites is an uncommon finding of triglyceride-rich lymph in the peritoneal cavity. There are a variety of reported etiologies for chylous ascites; however, the reporting of chylous ascites among AIDS/HIV-positive patients is quite uncommon. This finding as a complication of immune reconstitution inflammatory syndrome is even more unusual. Here we report a case (...) of an HIV-positive man with a history of colonic Mycobacterium avium complex who developed chylous ascites in the setting of increasing CD4 counts and decreasing viral load, suggestive of immune reconstitution inflammatory syndrome.

Full Text available with Trip Pro

2018 Proceedings (Baylor University. Medical Center)

24. Mycobacterium avium complex infection presenting as persistent ascites (PubMed)

Mycobacterium avium complex infection presenting as persistent ascites 29685915 2018 11 14 1488-2329 190 16 2018 Apr 23 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Mycobacterium avium complex infection presenting as persistent ascites. E515 10.1503/cmaj.180461 eng Journal Article Published Erratum Canada CMAJ 9711805 0820-3946 CMAJ. 2018 Apr 3;190(13):E394-E397 29615423 2018 4 25 6 0 2018 4 25 6 0 2018 4 25 6 0 ppublish 29685915 190/16/E515

Full Text available with Trip Pro

2018 CMAJ : Canadian Medical Association Journal

25. Energy Metabolism for the Patients With Pulmonary Mycobacterium Avium Complex

Energy Metabolism for the Patients With Pulmonary Mycobacterium Avium Complex Energy Metabolism for the Patients With Pulmonary Mycobacterium Avium Complex - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Energy Metabolism for the Patients With Pulmonary Mycobacterium Avium Complex The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03550820 Recruitment Status : Recruiting First Posted : June 8, 2018 Last Update Posted : June 8

2018 Clinical Trials

26. Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease (MAC2v3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03672630

2018 Clinical Trials

27. Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease. (PubMed)

Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease. Pulmonary Mycobacterium avium complex (pMAC) disease is a chronic, slowly progressive disease. The aim of the present study was to determine the association of six-minute walk test (6MWT) parameters with pulmonary function and the health-related quality of life (HRQL) in patients with pMAC disease.This cross-sectional study included adult

Full Text available with Trip Pro

2018 BMC pulmonary medicine

28. <i>In vitro</i> minimal inhibitory concentrations of rifampin and ethambutol, and treatment outcome in <i>Mycobacterium avium</i> complex lung disease. (PubMed)

In vitro minimal inhibitory concentrations of rifampin and ethambutol, and treatment outcome in Mycobacterium avium complex lung disease. Although it is known that the in vitro MICs of rifampin and ethambutol are poorly correlated with the clinical response in Mycobacterium avium complex (MAC) lung disease (MAC-LD), evidence for this is limited. This study investigated the association between treatment outcome and the in vitro MICs of rifampin and ethambutol in patients with MAC

2018 Antimicrobial Agents and Chemotherapy

29. Quantitative assessment of erector spinae muscles in patients with Mycobacterium avium complex lung disease. (PubMed)

Quantitative assessment of erector spinae muscles in patients with Mycobacterium avium complex lung disease. No reports exist regarding skeletal muscle involvement in patients with Mycobacterium avium complex lung disease (MAC-LD). The cross-sectional area of the erector spinae muscles (ESMCSA) reflects physical activity and can be assessed by computed tomography (CT). We investigated the relationship between ESMCSA and physiological parameters and prognosis in MAC-LD patients.In

2018 Respiratory medicine

30. Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density. (PubMed)

Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density. Vitamin D maintains calcium balance and has immunomodulatory effects. Only few studies have revealed the relationship between vitamin D and its associated factors in Mycobacterium avium complex (MAC) infection. This study aimed to investigate the effects of MAC infection on serum vitamin D, human cationic antimicrobial protein 18, its C-terminal 37

Full Text available with Trip Pro

2018 Medicine

31. Association between duration of aminoglycoside treatment and outcome of cavitary Mycobacterium avium complex lung disease. (PubMed)

Association between duration of aminoglycoside treatment and outcome of cavitary Mycobacterium avium complex lung disease. Although aminoglycosides are recommended for cavitary Mycobacterium avium complex lung disease (MAC-LD), the optimal duration of treatment is unclear. We investigated the association between duration of aminoglycoside treatment and outcomes in cavitary MAC-LD.Among patients diagnosed with macrolide-susceptible cavitary MAC-LD between 2000 and 2013, 101 patients who received

2018 Clinical Infectious Diseases

32. The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study. (PubMed)

The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study. Management of nontuberculous mycobacterial lung disease (NTMLD) consists of a long-term multi-drug antibiotic regimen, yet many patients do not achieve culture conversion. We estimated the NTMLD-related direct medical costs in Canada, France, Germany, and the United Kingdom (UK) among refractory patients who were infected with Mycobacterium (...) avium complex (MAC), without concomitant cystic fibrosis, tuberculosis, or HIV.We conducted a retrospective observational physician survey of nationally representative samples. The survey captured anonymized information about patients' treatment histories for NTMLD-related health care resource utilization over a 24-month period. We summarized NTMLD-related resource use and estimated the total economic burden, from each country's health care payer perspective.In total, 59 physicians provided data

Full Text available with Trip Pro

2018 BMC health services research

33. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study. (PubMed)

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study. Rationale Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). Objectives To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT

2018 American Journal of Respiratory and Critical Care Medicine

34. Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study. (PubMed)

Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study. Little is known about the role of Aspergillus precipitating antibody (APAb) in patients with Mycobacterium avium complex lung disease (MAC-LD).We investigated the clinical characteristics of patients with MAC-LD positive for APAb.We conducted a cross-sectional study targeting patients with MAC-LD. APAb was checked in all participants. Clinical variables included laboratory data

2018 Respiratory medicine

35. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. (PubMed)

High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. The incidence of nontuberculous mycobacterial (NTM) pulmonary disease caused by Mycobacterium avium complex (MAC) in apparently immune-competent people is increasing worldwide. We performed a systematic review of the published literature on five-year all-cause mortality in patients with MAC lung disease, and pooled the mortality rates to give an overall estimate of five-year mortality from

Full Text available with Trip Pro

2018 BMC Infectious Diseases

36. Mycobacterium Avium complex vertebral osteomyelitis in the absence of HIV infection: a case report and review. (PubMed)

Mycobacterium Avium complex vertebral osteomyelitis in the absence of HIV infection: a case report and review. Mycobacterium Avium Complex (MAC) is an established microbiologic cause of pulmonary disease, lymphadenitis, and disseminated disease in cases of advanced immune suppression. However, MAC manifesting as vertebral osteomyelitis is less common, and is particularly rare in the absence of Acquired Immunodeficiency Syndrome (AIDS). Prompt diagnosis of MAC vertebral osteomyelitis

Full Text available with Trip Pro

2018 BMC Infectious Diseases

37. Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. (PubMed)

Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. In bronchiectasis patients, chronic Pseudomonas aeruginosa (PA) infection has been associated with worse health-related quality of life (HRQL), but little is known about Mycobacterium avium complex lung disease (MACLD) patients in this context. This study aimed to evaluate HRQL and investigate the impact of chronic PA infection in MACLD patients.This cross-sectional

Full Text available with Trip Pro

2017 BMC pulmonary medicine

38. Outcomes of <i>Mycobacterium avium</i> complex lung disease based on clinical phenotype. (PubMed)

Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481

2017 European Respiratory Journal

39. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. (PubMed)

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. To determine if tedizolid is effective for pulmonary Mycobacterium avium complex (MAC) disease, and to use pharmacokinetics/pharmacodynamics to design optimal doses.We performed an exposure-response experiment in the hollow-fibre system model of intracellular MAC (HFS-MAC). We mimicked the tedizolid concentration-time profiles achieved in the lungs of patients treated once daily for 28 days

Full Text available with Trip Pro

2017 Journal of Antimicrobial Chemotherapy

40. A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease. (PubMed)

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease. To develop a thioridazine/moxifloxacin-based combination regimen for treatment of pulmonary infection due to Mycobacterium avium-intracellulare complex (MAC) that kills bacteria faster than the standard treatment regimen.Monocytes were infected with MAC and inoculated into the hollow-fibre system model for pulmonary MAC disease (HFS-MAC). We co-administered

Full Text available with Trip Pro

2017 Journal of Antimicrobial Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>